Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Rucaparib in High Genomic Loss of Heterozygosity and/or BRCA1/2-Mutated NSCLC (Lung-MAP Sub-Study, S1900A)

Conference Correspondent  - AACR & ASCO 2021 - Midyear Review

As a marker of homologous recombination deficiency, genomic loss of heterozygosity does not predict efficacy of rucaparib in advanced non–small-cell lung cancer (NSCLC).

While prior studies have shown robust efficacy leading to US Food and Drug Administration approval of poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-associated cancers, data in non–small-cell lung cancer (NSCLC) are much less clear. S1900A, a Lung-MAP substudy, evaluated the PARP inhibitor rucaparib in advanced-stage NSCLC harboring BRCA1/2 mutations or genomic loss of heterozygosity as a phenotypic marker of homologous recombination deficiency.1

Eligible patients were required to have a deleterious mutation in BRCA1 or BRCA2 and/or high (≥21%) genomic loss of heterozygosity. Other key eligibility criteria included advanced NSCLC that progressed on or after platinum-based chemotherapy and/or PD-L1 antibody and that progressed after the most recent line of systemic therapy, Zubrod performance status of 0 or 1, adequate organ function, no grade ≥3 hypercholesterolemia, no previous PARP inhibitor exposure, and no systemic therapy within 21 days of registration. Patients were stratified by histology into 2 cohorts: squamous and nonsquamous or mixed histology. With 40 eligible patients per cohort, the design had 91% power to rule out an overall response rate (ORR) of 15% if the true ORR was at least 35% at the 1-sided 5% level. A planned interim analysis on the first 20 patients evaluable for response per cohort required ≥3 responses to proceed to full study enrollment.1

A total of 64 patients were enrolled in the Lung-MAP Sub-Study, S1900A: 27 squamous NSCLC and 37 nonsquamous, of whom 59 were eligible for the study.1 Their median age was 66 years and most were male (56%).1 Almost all patients (98%) received 1 or 2 prior lines of treatment for stage IV disease.1 Biomarker selection included 36 (61%) patients with loss of heterozygosity only, 8 (14%) patients BRCA1 mutated, 15 (26%) patients BRCA2 mutated.1

Both cohorts were closed for futility with insufficient responses in the interim analysis populations.1 In the full study, 6 responses (4 nonsquamous and 2 squamous) were reported, such that the ORR was 10% (95% confidence interval [CI], 2%-18%).1 The disease control rate was 63% (95% CI, 50%-75%).1 The 6-month progression-free survival rate was 25% (95% CI, 4-46) in BRCA1/2-mutated patients and 50% (95% CI, 10-90) in patients with BRCA1/2-mutated homozygous NSCLC.1 Median overall survival was 7.8 months in the nonsquamous cohort and 8.2 months in the squamous cohort.1 The most frequent grade ≥3 adverse events were anemia (22%), lymphopenia (8%), fatigue (8%), transaminitis (5%), and thrombocytopenia (5%).1

Researchers concluded that the S1900A substudy failed to show the requisite level of efficacy for rucaparib in advanced NSCLC patients with high genomic loss of heterozygosity and/or a BRCA1/2 mutation. Genomic loss of heterozygosity as a phenotypic marker of homologous recombination deficiency does not predict sufficient activity of rucaparib in NSCLC. These results contrast with the high level of efficacy of PARP inhibitors in patients with BRCA-associated or high loss of heterozygosity in other tumor types. Underlying biologic differences in the genomic characteristics of these cancers compared with NSCLC may be responsible. Ongoing studies are examining this premise.1

Reference

1. Riess JW, Redman MW, Wheatley-Price P, et al. A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A). Presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2021. Abstract 9024.

Related Items
2021 Midyear Review: Non–Small-Cell Lung Cancer
Conference Correspondent  published on June 20, 2021 in AACR & ASCO 2021 - Midyear Review
Phase 2 Study of DM-CHOC-PEN in Patients with NSCLC with Central Nervous System Involvement
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Clinical Outcomes for Plasma-Based Genomic Profiling versus Tissue Testing in Advanced NSCLC (NILE)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Pooled Analyses of Immune-Related Adverse Events and Efficacy from IMpower130, IMpower132, and IMpower150
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Anti–PD-L1 Therapy in Combination with Chemotherapy versus Immunotherapy Alone in First-Line NSCLC with PD-L1 Score 1% to 49%
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Two-Year Update from CheckMate-9LA Study of Nivolumab plus Ipilimumab in Advanced NSCLC
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Comparison of Aumolertinib and Gefitinib in First-Line Treatment of EGFR-Mutated NSCLC
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Racial Disparities in Biomarker Testing and Clinical Trial Enrollment in NSCLC
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Capmatinib in MET Exon 14–Mutated Advanced NSCLC (GEOMETRY Mono-1 Study)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Atezolizumab versus Best Supportive Care After Adjuvant Chemotherapy for Resected NSCLC (IMpower010)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.